Gefitinib (ZD1839)

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Gefitinib (ZD1839) Chemical Structure

Gefitinib (ZD1839) Chemical Structure
Molecular Weight: 446.90

Validation & Quality Control

Product Use Citation(82)

Customer Product Validation(11)

Quality Control & MSDS

Related Compound Libraries

EGFR Inhibitors with Unique Features

  • Pan EGFR Inhibitor

    AZD8931 (Sapitinib) Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.

  • Most Potent EGFR Inhibitor

    Afatinib (BIBW2992) EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.

  • FDA-approved EGFR Inhibitor

    Lapatinib Approved by FDA for breast cancer.

  • Newest EGFR Inhibitor

    CO-1686 (AVL-301) Irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Product Information

  • Compare EGFR Inhibitors
    Compare EGFR Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.
Targets Tyr1173 (NR6W cells) [1] Tyr1173 (NR6wtEGFR cells) [1] Tyr992 (NR6wtEGFR cells) [1] Tyr992 (NR6W cells) [1]
IC50 26 nM 37 nM 37 nM 57 nM
In vitro Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell lines. The phosphorylation sites Tyr1173 and Tyr992 are less sensitive requiring higher concentrations of Gefitinib for inhibition. Gefitinib effectively blocks the phosphorylation of PLC-γ, with IC50 of 27nM, in NR6W cells. The NR6wtEGFR and NR6M cell lines has low levels of PLC-γ phosphorylation but the level in the NR6M cell line is more resistant to inhibition by Gefitinib with IC50 of 43 nM and 369 nM, respectively. Gefitinib inhibits Akt phosphorylations, with IC50 of 220 and 263nM, in the low-EGFR- and -EGFRvIII-expressing cell lines, respectively. Gefitinib in the dose range from 0.1 to 0.5μM significantly facilitates, rather than abrogates, colony formation of NR6M cells. However, at a concentration of 2 μM Gefitinib completely blocks NR6M colony formation. Gefitinib rapidly and in a dose-dependent manner inhibits EGFR and ERK phosphorylation up to 72 hours after EGF stimulation in both the high- and low-EGFR-expressing cell lines. [1] Gefitinib is the monolayer growth of these EGF-driven untransformed MCF10A cells with an IC50 of 20 nM. [2] The combination of Gefitinib (0.2 μM and 0.5 μM) with irradiation lead to a significant growth inhibition in LoVo cells, compared with radiation alone.. [3]
In vivo Gefitinib (100 mg/kg) improves the anti-tumor effect of radiotherapy in LoVo tumor xenografts. [3] Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts reveals a reversible dose-dependent inhibition of tumor growth because GEO tumors resumes the growth rate of controls at the end of the treatment. [4]
Features A potent EGFR tyrosine kinase inhibitor.

Protocol(Only for Reference)

Cell Assay: [1]

Cell lines NR6, NR6M and NR6W cells
Concentrations 0-2 μM
Incubation Time 72 hours
Method Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay.

Animal Study: [3]

Animal Models Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells.
Formulation 0.5% polysorbate
Dosages 100 mg/kg
Administration Once daily by oral administration (0.1 mL/10 g body weight) for 14 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)


[1] Pedersen MW, et al. Br J Cancer. 2005, 93(8), 915-923.

[2] Moasser MM, et al. Cancer Res. 2001, 61(19), 7184-7188.

view more

Clinical Trial Information( data from, updated on 2015-06-27)

NCT Number Recruitment Conditions Sponsor
Start Date Phases
NCT02447419 Not yet recruiting Solid Tumor Samsung Medical Center July 2015 Phase 2
NCT02326285 Not yet recruiting Non-squamous Non-small Cell Lung Cancer Stage II|Non-squamous Non-small Cell Lung Cancer Stage IIIA|Non-squamous Non-small Cell Lung Cancer Stage I  ...more Non-squamous Non-small Cell Lung Cancer Stage II|Non-squamous Non-small Cell Lung Cancer Stage IIIA|Non-squamous Non-small Cell Lung Cancer Stage IIIB|Activating EGFR Mutation|NSCLC AIO-Studien-gGmbH|AstraZeneca June 2015 Phase 2|Phase 3
NCT02387086 Not yet recruiting NSCLC Bai Jun|Shaanxi Provincial Peoples Hospital May 2015 Phase 2|Phase 3
NCT02374645 Recruiting Non-Small Cell Lung Cancer Hutchison Medipharma Limited|AstraZeneca April 2015 Phase 1
NCT02321293 Not yet recruiting Lung Cancer Lady Davis Institute|Jewish General Hospital February 2015 Phase 1

view more

Chemical Information

Download Gefitinib (ZD1839) SDF
Molecular Weight (MW) 446.90


CAS No. 184475-35-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 89 mg/mL (199.14 mM)
Ethanol 4 mg/mL (8.95 mM)
Water <1 mg/mL (<1 mM)
In vivo 0.5% methylcellulose/0.2% Tween 80 12 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine

Customer Product Validation (11)

Click to enlarge
Source Mol Syst Biol 2011 7, 486. Gefitinib (ZD1839) purchased from Selleck
Method qPCR analysis
Cell Lines glioblastoma cell lines
Concentrations 5 μM, 50 ng/ml
Incubation Time 6 h
Results We perturbed the activity of the EGFR by activating it using one of its ligands (EGF) and inhibiting it with a selective EGFR inhibitor (Gefitinib). As readout, we measured the transcriptional effect on SOCS2 (a modulator of STAT signaling), NR2E1(also known as TLX , a transcription factor believed to be important for neural stem cell renewal), yielding results compatible with a coupling between hub perturbation and transcriptional response.

Click to enlarge
Source Oncogene 2010 30, 737-750. Gefitinib (ZD1839) purchased from Selleck
Method Western blot
Cell Lines MEFs
Concentrations 1 μM
Incubation Time 48 h
Results We found that gefitinib, a specific EGFR inhibitor, almost completely recapitulated the results obtained by genistein (Figure a). Consistent with these results, we observed increased EGFR phosphorylation within 2 days of RECK depletion , with insignificant change in its protein amount (Figure b).

Click to enlarge
Source Carcinogenesis 2010 31, 1948–1955 . Gefitinib (ZD1839) purchased from Selleck
Method Luciferase assay
Cell Lines LNCaP-AI cells, LNCaP cells
Concentrations 20 μM
Incubation Time 24 h
Results EGF significantly stimulates the promoter activity of sPLA2-IIa gene in both LNCaP and LNCaP-AI cells (shown in LNCaP-AI cells), whereas Gefitinib and other inhibitors all tested downregulated the promoter activity both at the basal level (shown in LNCaP cells) and in response to EGF stimulation (shown in LNCaP-AI cells)

Click to enlarge
Source Carcinogenesis 2010 31, 1948–1955. Gefitinib (ZD1839) purchased from Selleck
Method ELISA
Cell Lines LNCaP-AI cells
Concentrations 20 μM
Incubation Time 24 h
Results Lapatinib, LY294002 and Bortezomib significantly inhibited sPLA2-IIa secretion, whereas Erlotinib, Gefitinib and CI-1033 had a moderate effect in LNCaP-AI cells .

Click to enlarge
Source J Immunother 2011 34(4), 372-81. Gefitinib (ZD1839) purchased from Selleck
Method Cytotoxicity assay
Cell Lines NK-92 cells/ lung cancer cells
Concentrations 10 μM
Incubation Time 24 h
Results Susceptibility of lung cancer cells to cytolytic activity of NK cells was significantly increased by treatment with EGFR inhibitors (erlotinib/gefitinib) and was reversed by blocking step using mAb against NKG2D before the assay in all lung cancer cells.

Click to enlarge
Source Antiviral Res 2010 89, 64-70. Gefitinib (ZD1839) purchased from Selleck
Method Proliferation assay, Plaque reduction test, Western blot, Real-time PCR
Cell Lines Hep2 cells
Concentrations 0.01-1000 μM
Incubation Time
Results While for Gefitinib concentrations between 100 μM and 0.01 μM the proliferation rate was almost 100% of the controls, only at concentrations of 1000 μM a slight (24%) decline in proliferation was observed (Fig.A). IC50 values of Gefitinib for plaque size reduction were calculated by dividing plaque size by total size of one tissue culture plate well for each compound concentration. A non-linear regression fit curve analysis from the calculated values revealed for plaque size reduction an IC50 value of 4.93μM for Gefitinib(Fig. B).The analysis of phosphorylated EGFR and of the downstream signaling kinases ERK1/2 in cell lysates of the assay confirmed the dose dependency of the antiviral effect of Gefitinib. Kinase activ-ities were completely suppressed at concentrations above 1μM as determined by Western blot analysis. VACV proteins were not detectable between 10 μM and 100 μM in Western blot analysis anymore (Fig. C).

Click to enlarge
Source Antiviral Res 2010 89, 64-70. Gefitinib (ZD1839) purchased from Selleck
Method Immunofluorescence
Cell Lines Hep2 cells
Concentrations 0.01-1000 nM
Incubation Time 96 h
Results As shown in Fig. A, an immunofluorescent staining of a plaque reduction test was performed 96 h after viral infection. VACV infected cells were treated with 1000 μM, 1 μM or 0.01 μM Gefitinib and compared to uninfected cells after 96 h incubation. At concentrations of 1000 μM Gefitinib virus induced plaques were rarely found in cell culture and infected cells only could be identified by fluorescent staining of orthopoxvirus proteins (green) but not by light microscopy. At this Gefitinib concentration EGFR phosphorylation was completely suppressed in the cells and even the uninfected, untreated control cells show a stronger pEGFR signal (control, red). Occasionally found plaques, visible by flourescence microscopy only, showed a very compact shape with minimal disruption in its center. At the lower Gefitinib concentrations plaques showed an increasing number of infected and pEGFR positive cells (merge, yellow) and a surround-ing small zone of solely pEGFR positive cells (red). The lower the Gefitinib concentration the more plaques with a disrupted center were observed (1μM and 0.01μM). Most of the cells localized in the center of the plaque were positive for orthopoxvirus infection but negative for pEGFR ( Fig. B).

Click to enlarge
Source Mol Biosyst 2011 7, 3223-33. Gefitinib (ZD1839) purchased from Selleck
Method Immunoprecipitation/Western blotting
Cell Lines
Concentrations 5 μM
Incubation Time 0-1 h
Results In the presence of the EGFR tyrosine kinase inhibitor Z D1839 (Iressa) revealed that the observed increase in binding between PCM1 and Azi1 is specific to EGFs timulation and requires E GFR activation.

Click to enlarge
Source Int J Proteomics 2011 215496. Gefitinib (ZD1839) purchased from Selleck
Method CEER assay
Cell Lines H358 cell line
Concentrations 0.01-10 μM
Incubation Time 4 h
Results HER1 and/or HER2 pathway-activated cell lines, H358 , had their activation blocked by the HER1/2 kinase inhibitors Gefitinib.

Click to enlarge
Source 2010 Dr. Zhang of Tianjin Medical University. Gefitinib (ZD1839) purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-5 nM
Incubation Time 24 h

Click to enlarge
Source 2010 Dr. Vicky Tin from University of Hong Kong. Gefitinib (ZD1839) purchased from Selleck
Method MTT assay
Cell Lines H1299 cells, H358 cells, H25 cells, HCC827 cells
Concentrations 0-400 nM
Incubation Time 72 h

Product Use Citation (82)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related EGFR Products

  • Poziotinib (HM781-36B)

    Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.

  • CL-387785 (EKI-785)

    CL-387785 (EKI-785) is an irreversible, and selective EGFR inhibitor with IC50 of 370 pM.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Erlotinib HCl (OSI-744)

    Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992)

    Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • AZD9291

    AZD9291 is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

  • Lapatinib

    Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

  • AG-490 (Tyrphostin B42)

    AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

  • Rociletinib (CO-1686, AVL-301)

    Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2.

  • Canertinib (CI-1033)

    Canertinib (CI-1033) is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4. Phase 3.

    Features:First kinase inhibitor to show irreversible activity and to have entered clinical trials (serving as a template for further development).

Recently Viewed Items

Tags: buy Gefitinib (ZD1839) | Gefitinib (ZD1839) ic50 | Gefitinib (ZD1839) price | Gefitinib (ZD1839) cost | Gefitinib (ZD1839) solubility dmso | Gefitinib (ZD1839) purchase | Gefitinib (ZD1839) manufacturer | Gefitinib (ZD1839) research buy | Gefitinib (ZD1839) order | Gefitinib (ZD1839) mouse | Gefitinib (ZD1839) chemical structure | Gefitinib (ZD1839) mw | Gefitinib (ZD1839) molecular weight | Gefitinib (ZD1839) datasheet | Gefitinib (ZD1839) supplier | Gefitinib (ZD1839) in vitro | Gefitinib (ZD1839) cell line | Gefitinib (ZD1839) concentration | Gefitinib (ZD1839) nmr
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description
Contact Us